Form 4: Immunic Director Barclay Phillips Granted 150,000 Stock Options

Immunic, Inc. Director Barclay A. Phillips was granted 150,000 stock options with an exercise price of $0.7729, vesting monthly over one year.

Summary

• Barclay A. Phillips, a Director of IMMUNIC, INC. (IMUX), was granted 150,000 stock options.
• The transaction occurred on June 5, 2025.
• The stock options have an exercise price of $0.7729 per share.
• The options vest in monthly increments over a period of one year from the grant date.
• The expiration date for these options is June 5, 2035.
• Following this transaction, Barclay A. Phillips beneficially owns 150,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns management's interests with shareholder value creation, indicating continued commitment. It is a standard compensation practice and does not reflect operational performance directly.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• The exercise price of $0.7729 provides a clear benchmark for future stock performance relative to the grant.

Future Outlook

The stock options will vest in monthly increments over a one-year period from the grant date, indicating a future increase in the director's exercisable equity holdings.

Industry Context

The grant of stock options is a common form of equity compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to attract, retain, and incentivize leadership by aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across various industries, including biotechnology, aligning with global benchmarks for corporate governance and executive incentives.
• The vesting schedule over one year is typical for such grants, ensuring continued commitment from the director.
• The exercise price being set at a specific value (not necessarily market price at grant, but a defined value) is standard for option grants.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Director (Barclay A. Phillips): Receives equity compensation, increasing their stake and potential future wealth tied to the company's stock performance.

Next Steps

• The stock options will vest in monthly increments over the next year, leading to an increase in the director's exercisable shares.

Key Dates

Recommendation

Keywords

Immunic, IMUX, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership